Tissue microarrays for testing molecular biomarkers of cervical intraepithelial neoplasia: Feasibility study

Acta Cytologica

Volumn 50, Issue 2, 2006, Pages 123-128

  Schneider, Volker ^a,b  

^a Pathology Laboratories   (Germany)

^b NONE   (Germany)

Author keywords

Cervical intraepithelial neoplasia; Mass screening; Tissue microarrays

Indexed keywords

C4.8 MARKER; EOSIN; HEMATOXYLIN; MOLECULAR MARKER; PARAFFIN; PROTEIN P16INK4A; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; EVALUATION; FEASIBILITY STUDY; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASS SCREENING; PRECANCER; PRIORITY JOURNAL; RELIABILITY; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; TISSUE SECTION; UTERINE CERVIX CARCINOMA;

EID: 33645465389     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000325919     Document Type: Article

References (34)

1. Rimm DL: Impact of microarray technologies on cytopathology: Overview of technologies and commentary on current and future implications for pathologists and cytopathologists. Acta Cytol 2001;41:111-114
2. Von Knebel Doeberitz M: New markers for cervical dysplasia to visualize the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38:229-242
3. Syrjänen KJ: Immunohistochemistry in assessment of molecular pathogenesis of cervical carcinogenesis. Eur J Gynaecol Oncol 2005;26:5-19
4. Malinowski DP: Molecular diagnostic assays for cervical neoplasia: Emerging markers for the detection of high-grade cervical disease. Biotechniques 2005;38:S17-S23
5. Keating JT, Cviko A, Riethdorf S, Riethdorf L, Quade BJ, Sun D, Duensing S, Sheets EE, Munger K, Crum CP: Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus related cervical neoplasia. Am J Surg Pathol 2001;25:884-891
6. Kruse AJ, Skaland I, Janssen EA, Buhr-Wildhagen S, Klos J, Arends MJ, Baak JP: Quantitative molecular parameters to identify low risk and high risk early CIN lesions: Role of markers of proliferative activity and differentiation and Rb availability. In J Gynecol Pathol 2004;23:100-109
7. Kruse AJ, Baak JP, Janssen EA, Bol MG, Kjellevold KH, Fianne B, Lovslett K, Bergh J: Low and high risk CIN 1 and 2 lesions: Prospective predictive value of grade, HPV, and Ki67 immunoquantitative variables. J Pathol 2003;199;462-470
8. Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH, Coleman N: Minichrome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999;5:2121-2132
9. Prpic NK, Parker M, Sampson S, Hessling J, Taylor A, Fischer T: Correlation of p16, MCM2, and Cyclin E as molecular markers for cervical disease in IHC and ICC formats (abstr). Mod Pathol 2005;18:200A
10. Malinowski DP, Avissar PL, Li H, Hall LB, Parker MS, Taylor AJ, Fischer TJ: Aberrant S-phase induction in high-grade cervical disease: Specific over-expression of minichromosome maintenance protein 2 (MCM2) as a diagnostic marker for moderate-severe dysplasia and cervical carcinoma (abstr). Cytopathology 2005;16:S19
11. Li F: Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005;92:212-216
12. Branca M, Giorgi C, Santini D, DiBonito L, Ciotti M, Costa S, Benedetto A, Casolati EA, Favalli C, Paba P, DiBonito B, Mariani L, Syrjänen S, Bonifacio D, Accardi L, Zanconati F, Syrjaenen K, HPV Pathogen ISS Study Group: Survivin as a marker of cervical intraepithelial neoplasia and high risk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer. Am J Clin Pathol 2005;124:113-121
13. van de Putte G, Kristensen GB, Lie AK, Baekelandt M, Holm R: Cyclins and proliferation markers in early squamous cell cervical carcinoma. Gynecol Oncol 2004;92:40-46
14. Wang SS, Trunk, M, Schiffman M, Herrero R, Sherman ME, Burk RD, Hildesheim A, Bratti MC, Wright T, Rodriguez AC, Chen S, Reichert A, von Knebel Doeberitz C, Ridder R, von Knebel Doeberitz M: Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004;13:1355-1360
15. Trunk MJ, Dallenbach-Hellweg G, Ridder R, Petty KU, Ikenberg H, Schneider V, von Knebel Doeberitz M: Morphologic characteristics of p16ink4a positive cells in cervical cytology samples. Acta Cytol 2004;48:771-782
16. Sotlar K, Stubner A, Diemer D, Menton S, Menton M, Dietz K, Wallwiener D, Kandolf R, Bultmann B: Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J Med Virol 2004;74:107-116
17. Molden T, Nygard JF, Kraus I, Karlsen F, Nygard M, Skare GB, Skomedal H, Thoresen SO, Hagmar B: Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV Proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005;114:973-976
18. Lie AK, Risberg B, Borge B, Sandstad B, Delabie J, Rimala R, Onsrud M, Thoresen S: DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 2005;97:908-915
19. Battifora H: The multitumor (sausage) tissue block: Novel method for immunohistochemical antibody testing. Lab Invest 1986;55:244-248
20. Kononen J, Bubendorf L, Kallionemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallionemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847
21. Bubendorf L: High through-put microarray technologies: From genomics to clinics. Eur Urol 2001;40:231-238
22. Bubendorf L, Nocito A, Moch H, Sauter G: Tissue microarrays (TMA) technology: Miniatuarized pathology archives for high-throughput in situ studies. J Pathol 2001;195:72-79
23. Fedor HL, De Marzo AM: Practical methods for tissue microarray construction. Methods Mol Med 2005;103:89-101
24. Kumar B, DeSilva M, Venter DJ, Armes JF: Tissue microarrays: A practical guide. Pathology 2004;36:295-300
25. Hewitt SM: Design, construction and use of tissue microarrays. Methods Mol Biol 2004;264:61-72
26. Alkushi A, Irving J, Hsu F, Dupuis B, Liu CL, Rijn M, Gilks CB: Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 2003;442:271-277
27. Kim JY, Lim SJ, Park K, Lee CM, Kim J: Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecol Oncol 2005;97:337-341
28. Hsu FD, Nielsen TO, Alkushi A, Dupuis B, Huntsman D, Liu CL, van de Rijn M, Gilks CB: Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol 2002;15:1374-1380
29. Rudiger T, Hofler H, Kreipe HH, Nizze H, Pfeifer U, Stein H, Dallenbach FE, Fischer HP, Mengel M, von Wasielewski R, Muller-Hermelink HK: Quality assurance in immunohistochemistry: Results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 2002;26:873-882
30. Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, Yeo CJ, Hruban RH: Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003;16:902-912
31. Bast RC Jr, Lilja H, Urban N, Rimm DL, Fritsche H, Gray J, Veltri R, Klee G, Allen A, Kim N, Gutman S, Rubin MA, Hruszkewycz A: Translational crossroads for biomarkers. Clin Cancer Res 2005;11:6103-6108
32. Schneider V: CIN prognostication: Will molecular techniques do the trick? Acta Cytol 2003;47:115-116
33. El Hamidi A, Kocjan G, Du M-Q: Clonality analysis of archival cervical smears: correlation of monoclonality with grade and clinical behavior of cervical intraepithelial neoplasia. Acta Cytol 2003;47:117-123
34. Wollscheid V, Kuehne-Heid R, Stein I, Jansen L, Kollner S, Schneider A, Durst M: Identification of a new proliferation associated protein NET-1/c4.8 characteristic for a subset of high grade cervical intraepithelial neoplasia and cervical carcinoma. Int J Cancer 2002;99:771-775